Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13040223 | 0.96 | BRD4 (0.42) | BRD4BRD2PAX8 | |
| SCHEMBL13040303 | 0.90 | BRD4 (0.45) | BRD4BRD2PAX8 | |
| SCHEMBL13040308 | 0.72 | ALDH1A1 (0.38) | PAX8 | |
| SCHEMBL13040283 | 0.71 | BRD4 (0.38) | BRD4BRD2PAX8 | |
| SCHEMBL13040295 | 0.70 | PAX8 (0.31) | PAX8ITGB1ITGA2 | |
| SCHEMBL13040280 | 0.67 | BRD4 (0.42) | BRD4BRD2PAX8 | |
| SCHEMBL1564364 | 0.65 | — | — | |
| SCHEMBL428490 | 0.65 | — | — | |
| SCHEMBL120927 | 0.65 | — | — | |
| Methylpyrrolidone SCHEMBL26931672 | 0.64 | BRD4 (0.81) | BRD4BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280238-A1 | INTRAMOLECULAR AZIDE-ALKYNE CYCLOADDITION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-11-04 | — | — | US | disclosed |
| US-20100280238-A1 | INTRAMOLECULAR AZIDE-ALKYNE CYCLOADDITION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-11-04 | — | — | US | disclosed |
| WO-2010127088-A2 | INTRAMOLECULAR AZIDE-ALKYNE CYCLOADDITION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280238-A1 | INTRAMOLECULAR AZIDE-ALKYNE CYCLOADDITION | APOBEC3G, HYOU1, HTR3C | BRD4 883/4885BRD2 683/4885PAX8 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.